Resumo

CANTILLO, Jorge de Jesús  e  GERARDO ROJAS, Wilmer. Fabry disease Description of a case and its evolution with enzyme replacement therapy. Acta Med Colomb [online]. 2014, vol.39, n.2, pp.202-206. ISSN 0120-2448.

Fabry disease is an inherited disorder of progressive and multisystemic lysosomal storage of glycosphingolipids catabolism, X-linked, which is caused by a defect in the gene that catalyzes the lysosomal enzyme alpha-galactosidase A (alpha-GAL A), and causes the intracellular deposition, especially of globotriaosyl ceramide (Gb3) in the vascular endothelium and other tissues. Partial or total deficiency of the lysosomal enzyme activity leads to the inability to catabolize certain glycosphingolipids causing the main damage, namely the intralysosomal deposit of Gb3 substrate in different cell types. In particular, vascular endothelial cells are progressively affected, which may cause tissue ischemia and infarction. It is a progressive disease that causes manifestations derived from the dysfunction of the organ affected by the deposits, mainly kidney, heart, nervous system, gastrointestinal tract and skin, although any organ and system of the economy may be involved. Before the availability of enzyme replacement therapy, treatment for this condition consisted mainly of symptomatic care and no specific remedies. Clinical characteristics and evolution of a 47 year old man with Fabry disease on enzyme replacement therapy are described. (Acta Med Colomb 2014; 39: 202-206).

Palavras-chave : Fabry disease; alpha-galactosidase A; lysosomal storage disease; globotriaosyl - ceramide; enzyme replacement therapy.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )